<p>Inhibition of infection using HIV-1+ sera and multiple viral forms (pseudovirus, biological isolate, original IMC and IMC.LucR) of CM235.2 (A) and ETH2220.11B (B) in the TZM-bl assay, using the cell-line encoded firefly luciferase reporter endpoint. Inhibition of infection using HIV-1+ sera and CM235.LucR (C) and ETH2220.LucR (D) in the TZM-bl and PBMC assay with three different donor PBMC as assay targets, using the IMC-encoded Renilla luciferase reporter endpoint. Values are the reciprocal sera dilution at which RLU was reduced by 50% compared to the level in virus control wells. Horizontal lines represent the threshold of detection (1:40 sera dilution); values at or under the line indicate 50% inhibition was not reached.</p
This protocol, similarly to the protocol of Labcode 2, describes a pseudovirus assay that measures n...
<p><sup>a</sup>The neutralizing titer (IC<sub>50</sub>) is defined as the reciprocal of the plasma d...
<p>Neutralizing activity of 6 plasma samples against 5 B-Env- and 6 C-Env-recombinant viruses was ev...
<p>% Neutralization obtained with 1∶20 plasma dilution, ≥80% reduction in virus titer is highlighted...
<p>A panel of eleven HIV+ CRF_01 AE sera was assayed against two tier 1 (C3347.c11 and C1080.c03) an...
<p><b>A</b>. <b>Neutralization with epitope-specific inhibitors</b>. NL.LucR-CM235.ecto was tested ...
<p>% Neutralization obtained with 1∶20 plasma dilution, ≥80% reduction in virus titer is highlighted...
<p><b>A</b>-<b>C</b>. <b>Neutralization sensitivity of three tier 2 subtype B IMC.LucR transmitted/f...
<p>Titrations of IMC.LucR only, CM235.LucR and ETH2220.LucR (A), of CM235.2 Env-based viruses (B) an...
<p>Neutralizing titers corresponding to 50% inhibition of the reporter luciferase activity (compared...
OBJECTIVE: Using clinical isolates from a recent passive immunization trial with antibody 2G12, we p...
AbstractEffective vaccine development for human immunodeficiency virus type 1 (HIV-1) will require a...
<div><p>Standardized assays to assess vaccine and antiviral drug efficacy are critical for the devel...
<p>Neutralizing activity of immune serum to 18 clade A, B, and C HIV-1 isolates was measured in the ...
(A) Inhibition of HIV-1HXB2 Env fusion using equal titrated concentrations of eCD4-Igmim2 (blue), en...
This protocol, similarly to the protocol of Labcode 2, describes a pseudovirus assay that measures n...
<p><sup>a</sup>The neutralizing titer (IC<sub>50</sub>) is defined as the reciprocal of the plasma d...
<p>Neutralizing activity of 6 plasma samples against 5 B-Env- and 6 C-Env-recombinant viruses was ev...
<p>% Neutralization obtained with 1∶20 plasma dilution, ≥80% reduction in virus titer is highlighted...
<p>A panel of eleven HIV+ CRF_01 AE sera was assayed against two tier 1 (C3347.c11 and C1080.c03) an...
<p><b>A</b>. <b>Neutralization with epitope-specific inhibitors</b>. NL.LucR-CM235.ecto was tested ...
<p>% Neutralization obtained with 1∶20 plasma dilution, ≥80% reduction in virus titer is highlighted...
<p><b>A</b>-<b>C</b>. <b>Neutralization sensitivity of three tier 2 subtype B IMC.LucR transmitted/f...
<p>Titrations of IMC.LucR only, CM235.LucR and ETH2220.LucR (A), of CM235.2 Env-based viruses (B) an...
<p>Neutralizing titers corresponding to 50% inhibition of the reporter luciferase activity (compared...
OBJECTIVE: Using clinical isolates from a recent passive immunization trial with antibody 2G12, we p...
AbstractEffective vaccine development for human immunodeficiency virus type 1 (HIV-1) will require a...
<div><p>Standardized assays to assess vaccine and antiviral drug efficacy are critical for the devel...
<p>Neutralizing activity of immune serum to 18 clade A, B, and C HIV-1 isolates was measured in the ...
(A) Inhibition of HIV-1HXB2 Env fusion using equal titrated concentrations of eCD4-Igmim2 (blue), en...
This protocol, similarly to the protocol of Labcode 2, describes a pseudovirus assay that measures n...
<p><sup>a</sup>The neutralizing titer (IC<sub>50</sub>) is defined as the reciprocal of the plasma d...
<p>Neutralizing activity of 6 plasma samples against 5 B-Env- and 6 C-Env-recombinant viruses was ev...